Chapter 4 90 35. Martinez-Moreno JM, Munoz-Castaneda JR, Herencia C, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012;303(8):F1136-44. doi:10.1152/ajprenal.00684.2011. 36. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertens (Dallas, Tex 1979). 2010;56(3):453-462. doi:10.1161/HYPERTENSIONAHA.110.152058. 37. Hruby A, O’Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging. 2014;7(1):59-69. doi:10.1016/j.jcmg.2013.10.006. 38. Keyzer CA,de Borst MH,van den Berg E,et al.Calcification Propensityand Survival among Renal Transplant Recipients. J Am Soc Nephrol. 2016;27(1):239-248. doi:10.1681/ASN.2014070670. 39. Montes de Oca A, Guerrero F, Martinez-Moreno JM, et al. Magnesium inhibits Wnt/betacatenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One. 2014;9(2):e89525. doi:10.1371/journal.pone.0089525. 40. Van Laecke S, Marechal C, Verbeke F, et al. The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant. 2011;26(7):23622369. doi:10.1093/ndt/gfq728. 41. Joris PJ, Plat J, Bakker SJ, Mensink RP. Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial. Am J Clin Nutr. 2016;103(5):1260-1266. doi:10.3945/ ajcn.116.131466. 42. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of allcause and cardiovascular mortality in hypertensive patients. Hypertens (Dallas, Tex 1979). 2001;37(5):1236-1241. 43. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and allcause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318-1327. doi:10.1016/j.jacc.2009.10.061. 44. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000;102(19):2353-2358. 45. Watson K V, Moldow CF, Ogburn PL, Jacob HS. Magnesium sulfate: rationale for its use in preeclampsia. Proc Natl Acad Sci U S A. 1986;83(4):1075-1078. 46. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem. 1992;110(2):169-173. 47. Iseri LT, French JH. Magnesium: nature’s physiologic calcium blocker. Am Heart J. 1984;108(1):188-193. 48. Afsar B, Elsurer R. The relationship between magnesium and ambulatory blood pressure, augmentation index, pulse wave velocity, total peripheral resistance, and cardiac output in essential hypertensive patients. J Am Soc Hypertens. 2014;8(1):28-35. doi:10.1016/j. jash.2013.10.006. 49. Pearson PJ, Evora PR, Seccombe JF, Schaff H V. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg. 1998;65(4):967-972.
RkJQdWJsaXNoZXIy MTk4NDMw